Biological age acceleration and extrahepatic multimorbidity in U.S. adults with MASLD
In a cross-sectional NHANES sample of 1,559 U.S. adults with MASLD, higher biological age acceleration, especially PhenoAge Acceleration, was associated with a greater burden of extrahepatic chronic conditions. This is an association, not proof of cause. [1]
Automatic summary · not editorially reviewed
The key findings
The cross-sectional analysis included 1,559 U.S. adults with MASLD from the NHANES 2017–March 2020 cycle. [1]
A one-standard-deviation increase in PhenoAge Acceleration was associated with binary multimorbidity (odds ratio 1.31, 95% confidence interval 1.07–1.62). [1]
The authors state that higher biological age acceleration, especially PhenoAge Acceleration, is associated with a greater burden of extrahepatic multimorbidity among adults with MASLD. [1]
The source at a glance
- Study type / format
- National cross-sectional study (abstract only).
- Population / context
- 1,559 U.S. adults with MASLD in the NHANES 2017–March 2020 cycle.
- Summary based on
- Study abstract
- Original publication
- June 30, 2026
MASLD sample and biological age measures
The authors analysed 1,559 adults with MASLD from the NHANES 2017–March 2020 cycle. MASLD was defined by a controlled attenuation parameter of at least 248 dB/m plus at least one cardiometabolic criterion. They examined three measures of biological age acceleration: KDM Acceleration, PhenoAge Acceleration and Homeostatic Dysregulation. Multimorbidity was based on 17 extrahepatic chronic conditions and analysed as a yes/no outcome, an ordered outcome and a count of conditions.
Supporting source [1]
PhenoAge acceleration linked to more conditions
In adjusted survey-weighted models, a one-standard-deviation increase in each biological age measure was associated with a higher multimorbidity burden. PhenoAge Acceleration showed the strongest and most consistent associations: for binary multimorbidity an odds ratio of 1.31 (95% confidence interval 1.07–1.62, p = 0.013) and for the ordinal outcome 1.40 (95% confidence interval 1.16–1.68). The abstract does not report the corresponding estimates for KDM Acceleration or Homeostatic Dysregulation.
Supporting source [1]
Cross-sectional design limits causal reading
The authors conclude that among adults with MASLD, higher biological age acceleration, especially PhenoAge Acceleration, is associated with a greater burden of extrahepatic multimorbidity. They describe MASLD as a systemic disorder linked to accelerated physiological decline and suggest biological age measures may help identify patients at high risk for accumulating comorbid disease. Because the analysis is cross-sectional, it cannot show whether accelerated biological ageing precedes or follows the extrahepatic conditions.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The study is cross-sectional, so it cannot establish timing or causation between biological age acceleration and extrahepatic multimorbidity. The abstract does not report estimates for KDM Acceleration or Homeostatic Dysregulation, nor details on how confounders were chosen.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ogbu C, Khokhar Z, Agbakoba G, Ogbu S, Bilal A, Ozumba S, Ezeani C, Umerah C, Okafor P. · europepmc.org · June 30, 2026